Related Experiment Video
Updated: Mar 27, 2026
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models
Jingnan Liu1, Tianxia Li1, Joseph M Thomas1
1Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA.
Abstract:
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause autosomal-dominant Parkinsonism with pleomorphic pathology including deposits of aggregated protein and neuronal degeneration. The pathogenesis of LRRK2-linked Parkinson's disease (PD) is not fully understood. Here, using co-immunoprecipitation, we found that LRRK2 interacted with synphilin-1 (SP1), a cytoplasmic protein that interacts with α-synuclein and has implications in PD pathogenesis. LRRK2 interacted with the N-terminus of SP1 whereas SP1 predominantly interacted with the C-terminus of LRRK2, including kinase domain. Co-expression of SP1 with LRRK2 increased LRRK2-induced cytoplasmic aggregation in cultured cells. Moreover, SP1 also attenuated mutant LRRK2-induced toxicity and reduced LRRK2 kinase activity in cultured cells. Knockdown of SP1 by siRNA enhanced LRRK2 neuronal toxicity. In vivo Drosophila studies, co-expression of SP1 and mutant G2019S-LRRK2 in double transgenic Drosophila increased survival and improved locomotor activity. Expression of SP1 protects against G2019S-LRRK2-induced dopamine neuron loss and reduced LRRK2 phosphorylation in double transgenic fly brains. Our findings demonstrate that SP1 attenuates mutant LRRK2-induced PD-like phenotypes and plays a neural protective role.
Insights
Synphilin-1 (SP1) protein protects against leucine-rich repeat kinase 2 (LRRK2) mutations linked to Parkinson's disease. SP1 reduces LRRK2 toxicity and neuronal loss, suggesting a protective role in Parkinson's pathogenesis.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of autosomal-dominant Parkinson's disease (PD).
- The precise mechanisms underlying LRRK2-linked PD pathogenesis remain incompletely understood.
- Synphilin-1 (SP1) is a cytoplasmic protein implicated in PD due to its interaction with alpha-synuclein.
Purpose of the Study:
- To investigate the interaction between LRRK2 and synphilin-1 (SP1).
- To determine the role of SP1 in modulating LRRK2-induced cellular toxicity and PD-like phenotypes.
Main Methods:
- Co-immunoprecipitation assays to confirm LRRK2-SP1 interaction.
- Cell culture experiments involving co-expression and siRNA knockdown.
- In vivo studies using Drosophila models expressing mutant G2019S-LRRK2 and SP1.
Main Results:
- LRRK2 directly interacts with SP1, with specific binding domains identified.
- Co-expression of SP1 with LRRK2 increased protein aggregation but attenuated LRRK2-induced toxicity and reduced LRRK2 kinase activity.
- Knockdown of SP1 exacerbated LRRK2 toxicity in cultured cells.
- In Drosophila, SP1 expression improved survival, locomotor activity, and protected against dopamine neuron loss induced by G2019S-LRRK2.
Conclusions:
- Synphilin-1 (SP1) plays a significant neural protective role in the context of LRRK2 mutations.
- SP1 attenuates mutant LRRK2-induced Parkinson's disease-like phenotypes.
- Targeting SP1 may offer a therapeutic strategy for LRRK2-linked Parkinson's disease.
Related Concept Videos
01:37Neural Regulation
01:15Parkinson's Disease: Overview